THERAPY DOSSIER · th-92ded2758575

Scutellarin parenteral solution

Nutraceutical · CHEMBL SEARCHED AND ZERO: compound_search on 'scutellarin' returned 0 hits, an explicit closed negative; this flavone glucuronide from Erigeron breviscapus is simply not indexed in ChEMBL v34.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: CHEMBL SEARCHED AND ZERO: compound_search on 'scutellarin' returned 0 hits, an explicit closed negative; this flavone glucuronide from Erigeron breviscapus is simply not indexed in ChEMBL v34.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22105928 ↗2012Mixed findings

Research on scutellarin parenteral solution's protective effects in rats with severe acute pancreatitis and multiple organ injuries.

RatOtherSprague-DawleyMaleParenteral (exact route not stated)After induction of severe acute pancreatitis, assessed at 6 and 12 hours

Model: Surgically induced severe acute pancreatitis with multiple organ injury (pancreas, liver, kidney, lung)

Survival did not differ between model control and treated groups. Alanine aminotransferase was lower with scutellarin at 12 hours and with Salvia miltiorrhiza at 6 and 12 hours; creatinine and amylase were lower with scutellarin at 6 hours; aspartate aminotransferase and blood urea nitrogen did not…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…